Pubblicazioni

Comunicare i risultati di ricerca è fondamentale. Questa priorità si riflette nell'elevato livello di pubblicazioni su riviste autorevoli e nel numero di articoli e partecipazioni nei principali congressi mondiali, soprattutto nel campo delle neuroscienze.

Di seguito, trovate alcuni esempi di pubblicazioni scritte da ricercatori di BIAL, da soli o in collaborazione con altri scienziati.

Tabs

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.

Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, et al.

Pubblicato: Epilepsia [Internet]. 2018;59(2):479–91.

Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures

Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P. Safety, Tolerability and Efficacy of Eslicarbazepine

Pubblicato: Drugs Aging [Internet]. 2018;null–null.

Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.

Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P.

Pubblicato: Epilepsy & behavior : E&B [Internet]. 2018;81:1–11.

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study.

Christian Elger.

Pubblicato: Epilepsia. 2009;50(3):454–63.

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

E. Ben-Menachem.

Pubblicato: Epilepsy Res Suppl. 2010;89(2-3):278–85.

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.

A. Gil-Nagel.

Pubblicato: Acta Neurol Scand. 2009;120(5):281–7.

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.

Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, et al..

Pubblicato: Epilepsia [Internet]. 2015;56(2):244–53.

Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: A pooled-analysis of data from two Phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Pubblicato: Eur J Neurol [Internet]. 2019;null–null.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, et al.

Pubblicato: Neurology [Internet]. 2018;90(21):e1849–e1857.

Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Ferreira JJ.

Pubblicato: Lancet Neurol. 2016;15(2):154–65.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, et al.

Pubblicato: Eur J Clin Pharmacol [Internet]. 2014;70(9):1059–71.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al.

Pubblicato: JAMA Neurol [Internet]. 2017;74(2):197–206.

Pre-Clinical

.

Effect of zamicastat in chronic treatment on right ventricle pressure overload in the rat monocrotaline lung injury model of pulmonary hypertension

Igreja, B., Pires, N., Moser, P. and Soares-da-Silva, et al.

Pubblicato: Hypertension. 2016;68(Suppl. 1: AP238).

Effect of Chronic Treatment With Zamicastat on Right Ventricle Pressure Overload in the Rat Monocrotaline Lung Injury Model of Pulmonary Hypertension.

Igreja, B., Pires, N., Moser, P. and Soares-da-Silva, et al.

Pubblicato: The FASEB Journal. 2017;31(1 Supplement 1070.7).

Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension.

Moura, E., Costa, C., Igreja B., Pires, et al.

Pubblicato: European Respiratory Society Meeting. 2020.

The Dopamine Beta-Hydroxylase Inhibitor Zamicastat Improves Survival in the Rat Monocrotaline Model of Pulmonary Arterial Hypertension.

Bonifacio M.J., Moura E., Sousa F., Igreja B., Pires N., Soares-da-Silva P.

Pubblicato: J Respir Crit Care Med. 2020;(201:A2088).

Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension.

Pires N., Igreja B., Magalhães L., Bonifácio M.J., Chevalier E., Soares-da-Silva P.

Pubblicato: Pulmonary Hypertension. 2020.

BIA 5-1058 is a new noncompetitive dopamine-β-hydroxylase inhibitor.

Bonifacio M.J., Sousa F., Igreja B., Loureiro A.I., Wright L.C., Soares-da-Silva P.

Pubblicato: Proceedings of the British Pharmacological Society. 2012.

In vitro Species Different Metabolism and CYP Phenotyping of Zamicastast.

Loureiro A.I., Rebouta J., Bonifácio M.J., Soares-da-Silva P.

Pubblicato: FASEB J. 2020;34(S1):1–1.

Clinical

.

A Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Zamicastat, in Healthy Male Volunteers.

Magalhães L., Rocha F., Falcão A., Gama H., Soares-da-Silva P.

Pubblicato: American Journal of Respiratory and Critical Care Medicine. 2020;201:A3816.

A Randomized, Double-Blind, Placebo-Controlled and Open-Label, Active-Controlled, 4-Period Crossover Trial to Evaluate the Effect of Zamicastat on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions.

Gama H., Magalhães L., Santos A., Soares-da-Silva P.

American Journal of Respiratory and Critical Care Medicine. 2020;201:A3815.

Drug-drug interaction study between zamicastat and bosentan in healthy subjects.

Guimarães A., Santos A., Ferreira J., Magalhães L., Gama H., Soares da Silva P.

Chest. 2020;157(6):A382.

Drug-drug interaction study between zamicastat and sildenafil in healthy subjects.

Santos A., Ferreira J., Gama H., Magalhães P. Soares -da-Silva P.

European Respiratory Journal 2020 56: 1458.

Drug-drug interaction study between zamicastat and treprostinil in healthy subjects.

Magalhães L., Guimarães A.M.R., Gana H., Magalhães P., Soares-da-Silva P.

American Journal of Respiratory and Critical Care Medicine 2021;203:A3615.

×

Si sta per uscire dal sito BIAL.

BIAL si assume la responsabilità per i contenuti del suo sito Web. Cliccando su "Continua" in basso, si entrerà in un sito web esterno a BIAL e fuori dal suo ambito di responsabilità.

ANNULLA CONTINUA